| Added by | celine.gongora |
|---|---|
| Group name | EquipeCG |
| Item Type | Journal Article |
| Title | Denosumab for treatment of hypercalcemia of malignancy |
| Creator | Hu et al. |
| Author | Mimi I. Hu |
| Author | Ilya G. Glezerman |
| Author | Sophie Leboulleux |
| Author | Karl Insogna |
| Author | Rasim Gucalp |
| Author | Waldemar Misiorowski |
| Author | Bennett Yu |
| Author | Paul Zorsky |
| Author | Diego Tosi |
| Author | Alberto Bessudo |
| Author | Arnaud Jaccard |
| Author | Giuseppe Tonini |
| Author | Wendy Ying |
| Author | Ada Braun |
| Author | Rajul K. Jain |
| Abstract | CONTEXT: Hypercalcemia of malignancy (HCM) in patients with advanced cancer is often caused by excessive osteoclast-mediated bone resorption. Patients may not respond to or may relapse after iv bisphosphonate therapy. OBJECTIVE: We investigated whether denosumab, a potent inhibitor of osteoclast-mediated bone resorption, reduces serum calcium in patients with bisphosphonate-refractory HCM. DESIGN, SETTING, AND PARTICIPANTS: In this single-arm international study, participants had serum calcium levels corrected for albumin (CSC) >12.5 mg/dL (3.1 mmol/L) despite bisphosphonates given >7 and ?30 days before screening. INTERVENTION: Patients received 120 mg sc denosumab on days 1, 8, 15, and 29 and then every 4 weeks. MAIN OUTCOME MEASURES: The primary endpoint was the proportion of patients with CSC ?11.5 mg/dL (2.9 mmol/L) (response) by day 10. Secondary endpoints included response by visit, duration of response, and the proportion of patients with a complete response (CSC ?10.8 mg/dL [2.7 mmol/L]) by day 10 and during the study. RESULTS: Patients (N = 33) had solid tumors or hematologic malignancies. By day 10, 21 patients (64%) reached CSC ?11.5 mg/dL, and 12 patients (33%) reached CSC ?10.8 mg/dL. During the study, 23 patients (70%) reached CSC ?11.5 mg/dL, and 21 patients (64%) reached CSC ?10.8 mg/dL. Estimated median response duration was 104 days. The most common serious adverse events were hypercalcemia worsening (5 patients, 15%) and dyspnea (3 patients, 9%). CONCLUSIONS: In patients with HCM despite recent iv bisphosphonate treatment, denosumab lowered serum calcium in 64% of patients within 10 days, inducing durable responses. Denosumab may offer a new treatment option for HCM. |
| Publication | The Journal of Clinical Endocrinology and Metabolism |
| Volume | 99 |
| Issue | 9 |
| Pages | 3144-3152 |
| Date | Sep 2014 |
| Journal Abbr | J. Clin. Endocrinol. Metab. |
| Language | eng |
| DOI | 10.1210/jc.2014-1001 |
| ISSN | 1945-7197 |
| Library Catalog | PubMed |
| Extra | PMID: 24915117 PMCID: PMC4154084 |
| Tags | Adult, Aged, Aged, 80 and over, Amgen, Antibodies, Monoclonal, Humanized, Bone Density Conservation Agents, Bone Resorption, clinic, Denosumab, Diphosphonates, Female, Gastrointestinal Diseases, Humans, Hypercalcemia, Hypophosphatemia, Internationality, Male, Middle Aged, Neoplasms, RANK Ligand, Serum Albumin, Therapeutics, Young Adult |
| Date Added | 2019/05/14 - 12:26:48 |
| Date Modified | 2019/10/24 - 16:26:10 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
